基于磷酸化组蛋白H2AX质谱定量分析的药品基因毒性杂质的毒效应导向高通量筛查方法研究

瞿敏敏 陈佳 徐斌 张雅姣 徐华 谢剑炜

引用本文: 瞿敏敏, 陈佳, 徐斌, 张雅姣, 徐华, 谢剑炜. 基于磷酸化组蛋白H2AX质谱定量分析的药品基因毒性杂质的毒效应导向高通量筛查方法研究[J]. 分析化学, 2021, 49(9): 1531-1539. doi: 10.19756/j.issn.0253-3820.211096 shu
Citation:  QU Min-Min,  CHEN Jia,  XU Bin,  ZHANG Ya-Jiao,  XU Hua,  XIE Jian-Wei. A Toxic Effect-Directed Screening Method for Genotoxic Impurities in Drugs Based on Mass Spectrometry Quantitative Analysis of Phosphorylated Histone H2AX[J]. Chinese Journal of Analytical Chemistry, 2021, 49(9): 1531-1539. doi: 10.19756/j.issn.0253-3820.211096 shu

基于磷酸化组蛋白H2AX质谱定量分析的药品基因毒性杂质的毒效应导向高通量筛查方法研究

    通讯作者: 徐华,E-mail:huarxu@163.com
  • 基金项目:

    国家重点研发计划项目(No.2018YFC1602600)和国家自然科学基金项目(No.21974151)资助。

摘要: 细胞中组蛋白H2AX磷酸化水平的变化能灵敏指示DNA断裂的毒性反应,基于此,本研究建立了药品中基因毒性杂质的同位素稀释高效液相色谱-串联质谱高通量筛查方法。H2AX及其磷酸化特异肽段的检出限分别为1和2 ng/mL,准确度和精密度均符合方法学要求。以两种重要的基因毒性杂质甲磺酸乙酯(EMS)及N-亚硝基二甲胺(NDMA)为代表,考察了两种具有不同药物代谢酶体系的受试细胞HepG2和HeLa,结果表明,EMS在两种受试细胞中均呈现基因毒性特点,而NDMA仅在具有相应药物代谢酶的HepG2细胞中呈现基因毒性。EMS与NDMA的检测灵敏度分别为0.06和0.03 μg/g,满足国际限量检出标准要求(EMS:0.6 μg/g,NDMA:0.3 μg/g)。将本方法应用于5种市售药片中基因毒性杂质的筛查,药片用水溶解后即直接与细胞孵育,药物活性成分及赋形剂不干扰测定,结果表明,本方法具有简便、灵敏度高和准确度好的特点,可用于药品中基因毒性杂质的快速高通量筛查。

English


    1. [1]

      LIU D Q, SUN M J, KORD A S. J. Pharm. Biomed., 2010, 51(5):999-1014.LIU D Q, SUN M J, KORD A S. J. Pharm. Biomed., 2010, 51(5):999-1014.

    2. [2]

      REDDY A V B, JAAFAR J, UMAR K, MAJID Z A, ARISA B, TALIB J. J. Sep. Sci., 2015, 38(5):764-779.REDDY A V B, JAAFAR J, UMAR K, MAJID Z A, ARISA B, TALIB J. J. Sep. Sci., 2015, 38(5):764-779.

    3. [3]

      BENIGNI R, BOSSA C. Curr. Comput. Aid. Drug, 2006, 2(2):169-176.BENIGNI R, BOSSA C. Curr. Comput. Aid. Drug, 2006, 2(2):169-176.

    4. [4]

      EMEA. European Medicines Agency announces recall of Viracept.[EB/OL].EMEA. European Medicines Agency announces recall of Viracept.[EB/OL].

    5. [5]

      EMEA. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity. EMA/459276/2018.EMEA. EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity. EMA/459276/2018.

    6. [6]

      ICH M7(R1). Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. 2017.[EB/OL]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_R1_Addendum_Step_4_2017_0331.pdf.ICH M7(R1). Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. 2017.[EB/OL]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Multidisciplinary/M7/M7_R1_Addendum_Step_4_2017_0331.pdf.

    7. [7]

      EMEA. Guideline on the Limit of Genotoxic Impurities[EB/OL]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002903.pdf.EMEA. Guideline on the Limit of Genotoxic Impurities[EB/OL]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002903.pdf.

    8. [8]

      FDA Guidance for Industry Specific Aspects of Regulatory GenotoxicityTests for Pharmaceuticals.[EB/OL]. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm074925.pdf.FDA Guidance for Industry Specific Aspects of Regulatory GenotoxicityTests for Pharmaceuticals.[EB/OL]. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm074925.pdf.

    9. [9]

      (国家药品监督管理局. 化学药物中亚硝胺类杂质研究技术指导原则(试行)). 2020.[2020-05-17]. http://www.nmpa.gov.cn/WS04/CL2138/377043.html.National Medical Products Administration. Technical Guidelines for Research on Nitrosamine Impurities in Chemical Drugs (for Trial Implementation). 2020.[2020-05-17]. http://www.nmpa.gov.cn/WS04/CL2138/377043.html.

    10. [10]

      KAKADIYA P R, CHANDRASHEKHAR T G, GANGULY S, SINGH D K, SINGH V. J. Pharmaceut. Biomed., 2011, 6(2):21-28.KAKADIYA P R, CHANDRASHEKHAR T G, GANGULY S, SINGH D K, SINGH V. J. Pharmaceut. Biomed., 2011, 6(2):21-28.

    11. [11]

      LIU Li-Yun, ZHANG Qian-Ru, SUN Lian-Fu, WANG Man-Man, GUO Wen-Min. China Pharmacist, 2014, 17(8):1274-1276. 刘立云, 张倩如, 孙连福, 王曼曼, 郭文敏. 中国药师, 2014, 17(8):1274-1276.

    12. [12]

      YI Da-Wei, ZHOU Yu, ZHAO Xiao-Dong, ZHANG Ya-Jie. Chin. J. Antibio., 2017, 42(6):521-525. 易大为, 邹宇, 赵晓东, 张亚杰. 中国抗生素杂志, 2017, 42(6):521-525.

    13. [13]

      ZHOU J, XU J, ZHENG X, LIU W, ZHENG F. J. Sep. Sci., 2017, 40(17):3414-3421.ZHOU J, XU J, ZHENG X, LIU W, ZHENG F. J. Sep. Sci., 2017, 40(17):3414-3421.

    14. [14]

      ELDER D P, SNODIN D J. J. Pharm. Pharmacol., 2009, 61(3):269-278.ELDER D P, SNODIN D J. J. Pharm. Pharmacol., 2009, 61(3):269-278.

    15. [15]

      XIE Han-Yi, LIN Yun-Liang, ZHANG Rui-Ling, WANG Shan-Shan, CHEN Xiang-Feng. Chin. J. Pharm. Anal., 2018, 38(10):1668-1676. 谢含仪, 林云良, 张瑞凌, 王珊珊, 陈相峰. 药物分析杂志, 2018,38(10):1668-1676.

    16. [16]

      KOPP B, KHOURY L, AUDEBERT M. Arch. Toxicol., 2019, 98(8):2103-2114.KOPP B, KHOURY L, AUDEBERT M. Arch. Toxicol., 2019, 98(8):2103-2114.

    17. [17]

      LEE Y, WANG Q, SHURYAK I, BRENNER DJ, TURNER H C. Radiat. Oncol., 2019, 14(150):1-10.LEE Y, WANG Q, SHURYAK I, BRENNER DJ, TURNER H C. Radiat. Oncol., 2019, 14(150):1-10.

    18. [18]

      ZHANG Sen, LIU Lu-Juan, CHEN Huan, HOU Hong-Wei, HU Qing-Yuan.Chin.J. Anal. Chem., 2016, 44(8):1291-1299. 张森, 刘鲁娟, 陈欢, 侯宏卫, 胡清源. 分析化学, 2016, 44(8):1291-1299.

    19. [19]

      SNODIN D J, MCCROSSEN S D. Regul. Toxicol. Pharmacol., 2013, 67(2):299-316.SNODIN D J, MCCROSSEN S D. Regul. Toxicol. Pharmacol., 2013, 67(2):299-316.

    20. [20]

      SMART D J, AHMEDI KP, HARVEY J S, LYNCH A M. Mutat. Res., 2011, 715(1-2):25-31.SMART D J, AHMEDI KP, HARVEY J S, LYNCH A M. Mutat. Res., 2011, 715(1-2):25-31.

    21. [21]

      GEORGE J, TSUCHISHIMA M, TSUTSUMI M. Cell Death Dis., 2019, 10(1):1801-1809.GEORGE J, TSUCHISHIMA M, TSUTSUMI M. Cell Death Dis., 2019, 10(1):1801-1809.

    22. [22]

      PIOTROWSKA H, KUCINSKA M, MURIAS M. Mol. Cell. Biochem., 2013, 383(1-2):95-102.PIOTROWSKA H, KUCINSKA M, MURIAS M. Mol. Cell. Biochem., 2013, 383(1-2):95-102.

    23. [23]

      GE Yu-Qi, YE Xiao-Xia, LE Jian, YANG Yong-Jian, WANG Yan. Chin. J. Pharm., 2020, 51(6):759-764. 葛雨琦, 叶晓霞, 乐健, 杨永健, 王彦. 中国医药工业杂志, 2020, 51(6):759-764.

    24. [24]

      JIANG Jun, ZOU Yun, SUN Li-Peng, LI Xiao-Dong. Chin. J. Anal. Lab., 2020, 39(2):245-248. 姜俊, 邹韵, 孙丽鹏, 李晓东. 分析试验室, 2020, 39(2):245-248.

    25. [25]

      GUO Chang-Chuan, LIU Qi, ZHANG Lei, ZHENG Jing, WANG Yong, YANG Shu-Juan, CHU Zhi-Jie, NIU Chong, XU Yu-Wen. Chin. J. Chromatogr., 2020, 38(11):1288-1293. 郭常川,刘琦, 张雷, 郑静, 汪勇, 杨书娟, 褚志杰, 牛冲, 徐玉文. 色谱, 2020, 38(11):1288-1293.

  • 加载中
计量
  • PDF下载量:  0
  • 文章访问数:  33
  • HTML全文浏览量:  7
文章相关
  • 收稿日期:  2021-01-31
  • 修回日期:  2021-04-06
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章